| METHODS
The OPTN database documents the presence of CD at the time of HTx; however, this is a subjective assessment by a single provider and does not accurately gauge the severity of CD. Academic progress provides a much more quantifiable assessment of CD and therefore is the primary focus of our analysis, with provider documentation of CD incorporated as a secondary analysis. The OPTN database was queried for all pediatric (<18 years of age) patients who underwent HTx between 2004 and 2014. These date ranges were chosen to coincide with the time when academic progress data collection began. For patients >5 years of age, centers report academic progress as WGL, DGL, or SE. These data are collected at the time of HTx and at subsequent follow-up visits. To minimize patients with missing CD data, the lowest recorded academic progress at the time of HTx or at any point during post-HTx follow-up was used in the analysis. Patients were divided into three groups based on their reported academic progress. Key variables were compared across groups. Post-transplant survival curves based on academic progress were constructed using the Kaplan-Meier method and compared using the log-rank test. A multivariable model was constructed using the Cox proportional hazards model. Variables included in the multivariable model were selected a priori and included age, gender, race, blood type, diagnosis (cardiomyopathy, congenital heart disease, retransplant, or other), listing status, VAD support, ECMO support, ventilator support, and inotropic support at the time of transplant. To determine potential risk factors for future DGL or the need for SE, logistic regression analysis was performed. The same variables selected a priori for the survival analysis were included in the logistic regression model to assess their contribution toward the development of either DGL or the need for SE during post-HTx follow-up.
At the time of transplantation and at post-HTx follow-up visits, centers report cognitive status as definite CD, probable CD, questionable CD, or no CD. Assessment of cognitive status is based on the subjective assessment of a single provider. A secondary analysis was performed substituting CD for academic progress. Patients were divided into two groups based on whether any concern for CD (questionable, probable, or definite) was ever reported at the time of HTx or in follow-up. Survival curves were generated based on the presence of CD using the Kaplan-Meier method and compared using the log-rank test. A multivariable model was constructed using the Cox proportional hazards model, adjusting for the same variables that were selected a priori for the primary analysis. Provider's assessment of the presence of CD at the time of HTx was also compared to academic progress at post-HTx follow-up to assess the ability of providers to gauge the presence of CD. All analyses were performed in STATA version 13 IC.
| RESULTS
A total of 2245 children were included in the analysis with documented academic progress at the time of transplantation or during post-HTx follow-up. Missing data were minimal, with only 2.6% of patients eligible for inclusion missing academic progress documentation. Of the patients with complete academic progress data, 1707 (76%) were WGL, 269 (12%) had DGL, and 269 (12%) required SE.
Baseline patient characteristics are summarized in Table 1 . There was no difference between academic progress groups based on gender, listing status, blood type, ethnicity, and the need for inotropes, VAD, ECMO, or ventilator support at the time of transplantation.
Patients with DGL were slightly older compared to the other groups and patients with congenital heart disease were more likely to have a DGL or require SE.
There was no significant difference in post-HTx survival between patients WGL and those who required SE (Figure 1 ). However, patients with DGL demonstrated worse post-HTx survival compared to patients WGL and those who required SE (log-rank P-value <.001).
This remained true in the multivariable analysis where the presence of DGL was an independent predictor of post-HTx graft loss (AHR 1.4, 95% CI 1.02, 1.79. P=.03) ( Table 2A ).
Given the possibility that any potential impact of CD may be more prominent in adolescent patients, a repeat analysis was performed examining only patients >11 years of age at the time of HTx. Similar to the primary analysis, patients with DGL demonstrated worse postHTx graft survival compared to patients WGL and those who required SE ( Figure 2 ). This difference remained in a multivariable analysis and DGL continued to be an independent risk factor for post-transplant graft loss (Table 2A) P=.005) were all associated with the development of either DGL or the need for SE at any time post-HTx. The need for VAD or ECMO support at the time of HTx did not appear to be risk factors for future delayed academic progress in our analysis.
Due to the potential for missing data to impact results when performing analyses using OPTN data, a missing value analysis was performed. As expected, the majority of patients with missing academic progress data were younger compared to those with complete data, as academic progress is only collected for patients aged ≥5 years of age. When excluding patients <5 years of age, 2.6% of patients were missing academic progress data. There was no difference between patients with missing and complete academic progress data in terms of diagnosis, gender, listing status, blood type, ethnicity, or the need for ventilator, inotrope, or VAD support. However, patients with missing academic progress data were younger and more likely to have been on ECMO at the time of HTx.
A total of 2959 children were included in the secondary analysis with complete cognitive status data. Of these patients, 1783
(60.3%) had no documented CD and 1176 had definite, probable,
or questionable CD documented at the time of HTx or in post-HTx follow-up.
Baseline patient characteristics are summarized in Table 3 . Patients with evidence of CD were younger, more likely to be male, have a diagnosis of congenital heart disease, and require ventilator support at the time of HTx. Differences were also noted in ethnicity and blood type between patients with and without CD.
There was no significant difference in post-transplant graft survival based on the presence of CD (Figure 3 ). This remained true when differences were adjusted for in a multivariable model (Table 2B) A total of 936 patients had provider assessment of CD at the time of HTx with documented academic progress during post-HTx follow-up, with 67 (7.2%) patients documented to have definite CD at HTx. Of these patients, 64.2% required SE and 11.9% had DGL in post-HTx follow-up. There were 719 (76.8%) patients without documented CD at the time of HTx. In this group, 2.9% required SE and 9.6% had DGL in post-HTx follow-up. There were 52 (5.6%) and 98 (10.5%) patients with documented probable and questionable CD at HTx, respectively. In both of these groups, the majority of patients This effect appears to be most prominent in older pediatric patients,
| DISCUSSION
where there was a trend toward improved graft survival in patients who required SE even compared to those WGL. So while this effect appears to be most significant in patients with DGL, there may also be an impact on patients WGL, suggesting that a strong social support structure may be critical to maintain compliance and improve outcomes. The importance of a strong social support structure is further strengthened by data from the adult population, where patients with mental retardation have significantly benefitted from HTx, provided they had a robust support system in place to assure compliance. 10 The presence of CD is inconsistently used across transplant centers as a criteria to determine transplant candidacy. 4 Richards et al.
recently surveyed a spectrum of pediatric solid organ transplant programs and found that CD was routinely used to assess transplant candidacy in only one-third of programs surveyed, while some programs reported that CD was never used as a criterion to evaluate transplant candidacy. Importantly, in this study the degree of CD impacted the frequency with which centers considered CD in listing, with centers more likely to take CD into consideration with severe or profound delays.
There are limited data available regarding post-transplant outcomes in pediatric patients with CD. However, multiple studies suggest that outcomes in patients with CD after solid organ transplantation are comparable to patients with no CD. T A B L E 2 Cox proportional hazards models assessing the impact of academic progress and the presence of cognitive delay on post-transplant graft survival F I G U R E 2 Post-transplant graft survival based on academic progress for patients >11 years of age. P-values from the log-rank test congenital heart disease was found to be a risk factor for delayed academic progress in our analysis. Patients undergoing their second transplant were also found to be at higher risk for future delayed academic progress. This finding may stem from the impact of a chronic illness with multiple or prolonged hospitalizations resulting in failure to maintain grade level. Interestingly, the need for VAD or ECMO pre-HTx did not appear to be a risk factor for future delayed academic progress in our analysis; however, the relatively small number of patients in these groups resulted in a low power to detect any potential effect of these factors.
Our secondary analysis utilized provider assessment of cogni- T A B L E 3 Baseline patient characteristics based on the presence of cognitive delay
| Limitations
Our study has inherent limitations. Our analysis utilized academic 
| CONCLUSIONS
Despite the fact that the presence of CD has previously been considered a relative contraindication to HTx, pediatric patients with CD can achieve similar outcomes after HTx compared to those without CD. These findings support the assertion that CD should not be viewed as a relative or absolute contraindication to HTx in pediatric patients; however, ensuring an adequate social support system is likely a critical step to optimize post-transplant outcomes for these patients.
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